



#11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: )  
)  
Applicant : Bejanin, et al. )  
) Grp./A.U. : 1645  
Appl. No. : 09/992,095 )  
) Examiner : Unassigned  
Filed : November 13, 2001 )  
)  
Title : **HUMAN CDNAS AND PROTEINS** )  
AND USES THEREOF. )

---

**PRELIMINARY AMENDMENT and  
RESPONSE TO THE NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures dated May 31, 2002, enclosed please find the following documents:

	<u>Document</u>	<u>Pages</u>
1)	Copy of the Notice to Comply	
2)	Substitute Sequence Listing Submission Statement	1 page
3)	Substitute Sequence Listing	pages
4)	CD-ROM containing the Substitute Sequence Listing in Computer Readable Form	1 CD-ROM
5)	Power of Attorney, Change of Correspondence Address; Statement under 37 CFR 3.73(b) (with enclosure)	3 pages
6)	Return Receipt Postcard	

Also, in response to the Notice to Comply with Requirements for Patent Applications containing Nucleotide and/or Amino Acid Disclosures, which was mailed by the Office on June 12, 2002, please amend the application as follows.

**In the sequence listing:**

Please replace the entire Sequence Listing with the substitute Sequence Listing enclosed herewith in paper form and CD-ROM computer readable form. The substitute Sequence Listing has

Appln. No. : 09/992,095  
Filed: November 13, 2001  
Page 2 of 2

been amended to correct the informalities indicated on the Raw Sequence Listing Report. Specifically, sections <220>-<223> have been added for SEQ ID NO:27, SEQ ID NO:29 and SEQ ID NO:71. Furthermore, the locations given in sections <220>-<223> of the alternative amino acid at position 29 of SEQ ID NO:30 and of the alternative amino acid at position 156 of SEQ ID NO:72 have been amended, and two sections <150>-<151> have been added since the present application claims the priority on the Provisional Applications Nos. 60/298,698 and 60/293,574. The nucleic acid and polypeptide sequences themselves have not been amended. No new matter has been added.

Please charge any additional fees, or credit overpayment to Deposit Account No. 50-1181.

Respectfully submitted,

GENSET CORPORATION

Date: 18 Aug., 2002 By: Kristen Walker P. 52,335 for  
John Lucas, Ph.D., J.D.  
Reg. No. 43,373

10665 Sorrento Valley Road  
San Diego, CA 92121-1609

Telephone: (868) 597-2610  
Facsimile: (858) 597-2600  
e-mail: john.lucas@genxv.com

*Certificate of Mailing*  
Date of Deposit: August 12, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, on the Date of Deposit shown above, postage prepaid and in an envelope addressed to the Assistant